SXTC - China SXT Pharmaceuticals, Inc.
| Previous Close | 0.7557 |
| Open | 0.7874 |
| Bid | 0.0000 x 900 |
| Ask | 0.0000 x 3000 |
| Day's Range | 0.6999 - 0.7900 |
| 52 Week Range | 0.6999 - 23.3500 |
| Volume | 101,934 |
| Avg. Volume | 123,561 |
| Market Cap | 20.392M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | 10.10 |
| EPS (TTM) | 0.0750 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Simply Wall St.
What Is China SXT Pharmaceuticals's (NASDAQ:SXTC) P/E Ratio After Its Share Price Tanked?
To the annoyance of some shareholders, China SXT Pharmaceuticals (NASDAQ:SXTC) shares are down a considerable 31% in...
- Simply Wall St.
Should You Worry About China SXT Pharmaceuticals, Inc.’s (NASDAQ:SXTC) ROCE?
Today we are going to look at China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) to see whether it might be an attractive...
- PR Newswire
China SXT Pharmaceuticals, Inc. Granted to Establish Taizhou Research Center for Advanced TCMP Engineering Techniques
TAIZHOU, China, Sept. 11, 2019 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, ...
- PR Newswire
China SXT Pharmaceuticals, Inc. Announces Filing of Annual Report on Form 20-F for Year Ended March 31, 2019
TAIZHOU, China, Aug. 19, 2019 /PR Newswire/ -- China SXT Pharmaceuticals, Inc. (SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), today announced that its Annual Report on From 20-F for the fiscal year ended March 31, 2019 has been filed with the U.S. Securities and Exchange Commission (the "SEC") on August 15, 2019. An electronic copy of the annual report on Form 20-F can be accessed on China SXT's website at http://www.sxtchina.com and on the SEC's website at www.sec.gov. Shareholders may receive a hard copy of China SXT's audited financial statement for the fiscal year ended March 31, 2019 free of charge upon request.
- PR Newswire
China SXT Pharmaceuticals, Inc. Receives New Pharmaceutical GMP Certificate
TAIZHOU, China, Aug. 12, 2019 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), announced today that it has been issued a new Certificate of GMP (Good Manufacturing Practice) for Pharmaceutical Products (the "Certificate") by the Food and Drug Administration of Jiangsu Province, China ("FDA"). The FDA staff conducted its on-site examination in accordance with government regulations.
- PR Newswire
China SXT Pharmaceuticals, Inc. Announces TCM Homologous Supplements Production
TAIZHOU, China, July 3, 2019 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacture, marketing and sales of Traditional Chinese Medicine Pieces ("TCMPs"), today announced that it has begun the production of TCM Homologous Supplements ("TCMHS"), a classification of health-supporting food used traditionally in China as TCM but which are also consumed as food. The Company recently reconstructed and assembled an 850-square-meter facility and received a "Food Manufacturing Certificate" issued by the local Food and Drug Administration, which granted the Company permission to produce TCMHS.
- PR Newswire
China SXT Pharmaceuticals, Inc. Being Admitted to Hi-tech Zone of Huangshan City in Anhui Province
TAIZHOU, China, May 22, 2019 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacture, marketing and sales of Traditional Chinese Medicine Pieces ("TCMPs"), announced today the launch of a strategic partnership with Future Science & Technology Park of Huangshan Hi-tech Zone and Huangshan Panjie Investment Co., Ltd. ("Panjie Investment") which is the shareholder and operator of the Park. In celebration of the event, a ribbon-cutting ceremony was hold on May 17, 2019 at the Future Science & Technology Park of Huangshan Hi-tech Zone, Anhui Province, making China SXT the first Nasdaq-listed company to be admitted to the Huangshan Hi-tech Zone.
- PR Newswire
China SXT Pharmaceuticals, Inc. Announces Pricing of a $15 Million PIPE Financing
TAIZHOU, China , April 17, 2019 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. ( NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, ...
- PR Newswire
China SXT Pharmaceuticals, Inc. Receives National High-tech Enterprise Qualification
TAIZHOU, China, Apr. 2, 2019 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (the "Company") (SXTC), a specialty pharmaceutical company focusing on the research, development, manufacture, marketing and sales of Traditional Chinese Medicine Pieces ("TCMPs"), announced today that its VIE subsidiary, Jiangsu Suxuantang Pharmaceutical Co., Ltd. ("Taizhou Suxuantang"), has been certified as National High-tech Enterprise (the "Certification") by the Ministry of Science and Technology of the PRC. The Certification is valid for three years and allows Taizhou Suxuantang to enjoy a preferential income tax rate of 15% versus the standard rate of 25%.
- PR Newswire
China SXT Pharmaceuticals, Inc. Announces Financial Results for the Six Months Ended September 30, 2018
TAIZHOU, China , March 28, 2019 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (the "Company") (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development, manufacture, ...
- ACCESSWIRE
4 Healthcare Stocks Looking To Finish Strong On Wednesday (1/30/19)
Premier Health Group (PHGRF) (PHGI), China SXT Pharmaceuticals Inc (SXTC), eHealth Inc (EHTH), and Ekso Bionics Holdings Inc (EKSO) represent four healthcare companies determined to provide the best quality of care for consumers in need. The Company has seen impressive gains over the last few months as a result of momentum gained from several key strategic investments meant to demonstrate to both investors and consumers that the Company is determined to invest in the future of its customers. Premier Health Group (PHGRF) (PHGI) announced earlier this week that, further to its new release dated January 10, 2019, the Company has acquired all outstanding securities of Cloud Practice Inc. As a result of the acquisition, Cloud Practice's Founders, including CEO Jordan Visco, and entire support team, consisting of several software developers and sales staff, will join and work alongside the Premier Health team to offer tools and resources providing for better efficiency on a day-to-day basis for both physicians and customers.
- PR Newswire
China SXT Pharmaceuticals, Inc. Announces Final Closing of Initial Public Offering
TAIZHOU, China and NEW YORK, Jan. 4, 2019 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (the "Company") (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development, manufacture, marketing and sales of Traditional Chinese Medicine Pieces ("TCMPs"), today announced the final closing of its initial public offering on January 3, 2019. Together with the first closing on December 31, 2018, the Company raised approximately $10.2 million in gross proceeds, before deducting underwriting discounts, commissions and other offering expenses, by issuing 2,546,275 ordinary shares at a public offering price of $4.00 per share. The shares are scheduled to commence trading on the NASDAQ Capital Market today at around 2:05 p.m. ET under the ticker symbol "SXTC".
